NM
ALGS icon

Newtyn Management’s Aligos Therapeutics ALGS Stock Holding History

Newtyn Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,771
Closed -$252K – 41
2024
Q2 		$252K Sell
28,771
-19,229
-40% -$338K 0.05% 39
2024
Q1 		$1.18M Sell
48,000
-2,200
-4% -$43.8K 0.23% 36
2023
Q4 		$833K Buy
50,200
+13,400
+36% +$230K 0.16% 39
2023
Q3 		$687K Buy
36,800
+800
+2% +$17.7K 0.17% 40
2023
Q2 		$874K Sell
36,000
-4,858
-12% -$130K 0.21% 37
2023
Q1 		$893K Sell
40,858
-19,142
-32% -$731K 0.18% 60
2022
Q4 		$1.43M Buy
60,000
+20,000
+50% +$504K 0.3% 44
2022
Q3 		$1.1M Buy
40,000
+1,516
+4% +$50.3K 0.24% 50
2022
Q2 		$1.16M Buy
+38,484
New +$1.31M 0.22% 58

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management's ALGS Position: Q3 2024 in Review

Newtyn Management sold out of Aligos Therapeutics (ALGS) in Q3 2024, closing a stake of 28,771 shares — an estimated $252K sold.

Newtyn Management first reported a position in ALGS in Q2 2022 and held it in 9 quarters. The position peaked at $1.43M in Q4 2022. 27 funds tracked by Wall St. Rank hold ALGS as of Q3 2024.

  • Newtyn Management reported no remaining Aligos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Newtyn Management sold 28,771 Aligos Therapeutics shares in Q3 2024, an estimated $252K.
  • Newtyn Management first reported a position in Aligos Therapeutics in Q2 2022 and held it in 9 quarters.
  • Newtyn Management's Aligos Therapeutics position peaked at $1.43M in Q4 2022.
  • 27 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2024.

Based on Newtyn Management's 13F filing for Q3 2024, filed 14 Nov 2024.